GLPwatch
Papers (12034)
Page 154 of 201, ranked by citation count.
- A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.
- [Modern strategies for the treatment of childhood obesity].
- Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.
- Semaglutide's Weight-Loss Benefits Were Sustained in a 2-Year Study.
- Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.
- ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine.
- GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
- The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis.
- Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?
- Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.
- Protective roles of liraglutide against brain injury of streptozotocin induced diabetic rats.
- Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.
- An Overview of the Burden of Illness and the Role of Once-Weekly Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.
- Liraglutide Mitigates Renal Injury in Diabetic Kidney Disease by Suppressing Podocyte Cholesterol Accumulation Through mTOR/VMP1-Regulated Autophagy.
- Neuroprotective Effects of Liraglutide and/or Rivastigmine Combination on the Rat Hippocampus.
- Microbes, mood, and metabolism/obesity: Pharmacological insights into the gut-obesity-depression triad.
- Effects of glucagon-like peptide 1 receptor signaling in the dorsolateral septum on ethanol operant self-administration and relapse behaviors.
- Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2.
- Reconsidering Semaglutide Use for Chronic Obesity in Patients of Asian Descent: A Critical Review.
- Treating with liraglutide an obese patient with type 2 diabetes mellitus and hereditary hemochromatosis.
- Bone morphogenetic protein-9 maybe an important factor which improves insulin resistance in PCOS.
- [Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)].
- Weight-loss dynamics with tirzepatide versus semaglutide.
- Early resuscitation with exendin-4 alleviates acute lung injury after hemorrhagic shock in rats.
- Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
- Potential protective role of GLP-1 receptor agonists for lithium-induced nephrotoxicity: a population-based observational study.
- What do I need to know about liraglutide (Saxenda), the glucagon-like peptide 1 receptor agonist for weight management in children with obesity?
- Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.
- The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis--what happens next? A personal viewpoint.
- Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function.
- Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
- Irisin and liraglutide combination therapy mitigates myocardial reperfusion injury in obese rats: Role of endoplasmic reticulum stress and apoptosis.
- The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.
- Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.
- Relapse in Anorexia Nervosa Associated With Tirzepatide: A Case Report.
- Oral Formulation and SGLT2i Interaction: Key Nuances in Semaglutide's Effect on Atrial Fibrillation.
- Tirzepatide vs. Semaglutide for Obesity Treatment.
- Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
- Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.
- The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.
- Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
- Roflumilast Enhances Liraglutide's Atrial Natriuretic Peptide-Dependent Suppression of Adrenal Aldosterone Secretion.
- Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.
- Treatment of persistent or recurrent type 2 diabetes after metabolic surgery.
- 68 Ga-NODAGA-EXENDIN-4 PET/CT in the Detection or the Exclusion of Occult Sporadic Insulinomas.
- National trends in prescription drug expenditures and projections for 2026.
- Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system.
- Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.
- Distinguishing among incretin-based therapies. Introduction.
- Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
- Redefining peptide therapeutics with semaglutide.
- [Diabetic ketoacidosis after switching insulin for exenatide].
- Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.
- Weight regain after bariatric surgery: A framework for management.
- Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States.
- Person-centered choice of anti-obesity pharmacotherapy.
- Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
- Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.
- Liraglutide for weight management: benefits and risks.